Latigo Biotherapeutics Inc. announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. In a Phase 1 first-in-human clinical trial, data showed that LTG-001 was well tolerated with rapid absorption. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute and chronic pain at its source. The Company also announced the appointment of world-renowned analgesic scientist Neil Singla, M.D., as chief medical officer.
“Opioid addiction is a national public health concern and Latigo Bio is dedicated to being part of the solution. Latigo intends to develop non-opioid drugs that have meaningful efficacy, rapid onset of action, and superior safety to standard of care with no central nervous system effects, thereby reducing the risk of addiction,” said Nima Farzan, Latigo’s chief executive officer. “These positive Phase 1 results of LTG-001 in healthy volunteers are encouraging and give us tremendous confidence we are moving in the right direction. We look forward to continuing to progress the clinical program for LTG-001 along with our robust pipeline so that we can provide alternatives for patients that reduce dependency and offer effective pain relief.”
LTG-001 Phase 1 Clinical Trial Results
Results from the Phase 1 clinical trial in 72 healthy subjects showed that LTG-001 was well tolerated and demonstrated rapid absorption with a Tmax of about 1.5 hours and predictable pharmacokinetics. Exposure was proportional across the dose range. Rapid onset of pain relief is critical for both acute and chronic pain management and achieving a Tmax in under two hours in this study indicates this may be possible. Additionally, no food effect was shown in the studied doses.
Also Read: Audax Private Equity to Acquire Avantor’s Clinical Services Unit
Latigo’s Phase 1 first-in-human clinical trial was designed to evaluate the safety and tolerability of single- and multiple-ascending oral doses, relative bioavailability, and food effect of LTG-001 versus placebo in healthy subjects.
World-leading Analgesic Scientist Neil Singla, M.D., Appointed as Chief Medical Officer
Latigo also announced the appointment of world-renowned analgesic scientist Neil Singla, M.D., as chief medical officer. Dr. Singla is the founder and past chief executive officer of Lotus Clinical Research, a world-renowned analgesic site and Clinical Research Organization combination. An expert in analgesic protocol design and implementation with a deep focus on minimizing variability in clinical trials with subjective endpoints, Dr. Singla has been instrumental in pioneering methodologies that enhance the rigor and outcomes of pain management studies.
“Dr. Singla’s extensive experience in analgesic protocol design and implementation will be invaluable as we work to address opioid addiction – one of the most critical public health issues of our time,” said Mr. Farzan. “We look forward to Neil’s leadership in advancing our pipeline of non-opioid pain medicines.”
“Latigo’s innovative approach to pain management can play a significant role in providing effective non-opioid therapies to patients,” said Dr. Singla. “Latigo’s mission aligns with my passion for advancing treatments for pain management, without the risk of dependency. I am honored to have the opportunity to work with the Latigo team to deliver these life-changing non-opioid alternatives to people who desperately need them.”
SOURCE: PRNewswire